InMode (NASDAQ:INMD) Updates Q4 Earnings Guidance

InMode (NASDAQ:INMD) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.61-0.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.53. The company issued revenue guidance of $109.5-110 million, compared to the consensus revenue estimate of $99.59 million.

NASDAQ INMD opened at $50.00 on Friday. The firm’s fifty day moving average price is $74.41 and its two-hundred day moving average price is $56.14. InMode has a fifty-two week low of $26.92 and a fifty-two week high of $99.27.

InMode (NASDAQ:INMD) last issued its quarterly earnings data on Tuesday, October 26th. The healthcare company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.05. InMode had a net margin of 46.06% and a return on equity of 46.95%. The company had revenue of $94.18 million for the quarter, compared to analysts’ expectations of $89.38 million. During the same quarter in the previous year, the firm posted $0.31 earnings per share. InMode’s revenue for the quarter was up 57.7% on a year-over-year basis.

Several equities analysts recently issued reports on INMD shares. Robert W. Baird boosted their target price on shares of InMode from $80.00 to $96.00 and gave the company an outperform rating in a report on Wednesday, October 27th. boosted their target price on shares of InMode from $80.00 to $100.00 and gave the company a buy rating in a report on Wednesday, October 27th. TheStreet lowered shares of InMode from a b- rating to a c rating in a report on Friday, October 1st. Needham & Company LLC dropped their target price on shares of InMode to $103.00 and set a buy rating on the stock in a report on Tuesday, October 12th. Finally, Barclays boosted their target price on shares of InMode from $60.00 to $85.00 and gave the company an overweight rating in a report on Wednesday, October 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of Buy and an average target price of $70.79.

An institutional investor recently raised its position in InMode stock. Morgan Stanley lifted its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 19.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 546,042 shares of the healthcare company’s stock after acquiring an additional 88,915 shares during the period. Morgan Stanley owned approximately 1.71% of InMode worth $51,699,000 at the end of the most recent reporting period.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.

Featured Article: Analyst Ratings Trading

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.